Omnicell (OMCL) Net Income towards Common Stockholders Growth (3y) (2013 - 2026)
Powered by 
Analysis
Omnicell (OMCL) Net Income towards Common Stockholders Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 187.42 Bn | 182.47 Bn | 7.27 Bn | -12.28% |
| 2 | Intuitive Surgical | 129.78 Bn | 124.69 Bn | 1.96 Bn | 24.56% |
| 3 | Medtronic | 120.53 Bn | 112.33 Bn | 6.34 Bn | 22.97% |
| 4 | Stryker | 116.28 Bn | 112.80 Bn | 4.50 Bn | 20.02% |
| 5 | Boston Scientific | 69.29 Bn | 68.99 Bn | 3.85 Bn | 51.47% |
| 6 | Edwards Lifesciences | 51.83 Bn | 47.68 Bn | 1.35 Bn | -7.83% |
| 7 | Alcon | 34.36 Bn | 32.91 Bn | 1.68 Bn | - |
| 8 | Dexcom | 33.17 Bn | 31.23 Bn | 830.00 Mn | 29.05% |
| 9 | Resmed | 32.94 Bn | 31.47 Bn | 861.22 Mn | 18.63% |
| 10 | Omnicell | 1.57 Bn | 1.28 Bn | 152.94 Mn | 91.64% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 91.64% |
| Mar 31, 2026 | 40.24% |
| Dec 31, 2025 | 58.53% |
| Sep 30, 2025 | -31.20% |
| Jun 30, 2025 | -14.65% |
| Mar 31, 2025 | -41.86% |
| Dec 31, 2024 | 4.25% |
| Sep 30, 2024 | -33.48% |
| Jun 30, 2024 | -43.24% |
| Mar 31, 2024 | -45.91% |
| Dec 31, 2023 | -42.24% |
| Sep 30, 2023 | -14.24% |
| Jun 30, 2023 | 40.99% |
| Mar 31, 2023 | -49.25% |
| Dec 31, 2022 | -48.67% |
| Sep 30, 2022 | -5.67% |
| Jun 30, 2022 | -17.20% |
| Mar 31, 2022 | 35.74% |
| Dec 31, 2021 | -1.86% |
| Sep 30, 2021 | 29.09% |